5-(4-methylphenyl)-1,2,4-oxadiazole | 545424-43-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(4-methylphenyl)-1,2,4-oxadiazole
• CAS: 545424-43-9
• 化学式: C₉H₈N₂O
• 分子量: 160.175
• InChiKey: AKBBVUGVXMJXJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(4-methylphenyl)-1,2,4-oxadiazole 、 2-(4-甲基苯基)恶唑 生成 4-(1,2,4-Oxadiazol-5-yl)benzaldehyde
  参考文献：
  名称：

  6-O-acyl ketolide antibacterials

  摘要：

  公式1中的6-O-Acyl ketolide类抗菌剂，其中R1，R2，R3，R4，W，X，X'，Y和Y'如本文所述，并且其中的取代基具有描述中指示的含义。这些化合物可用作抗菌剂。

  公开号：

  US20030220272A1
• 作为产物：
  描述：

  N-[(dimethylamino)methylene]-4-methylbenzamide 在 sodium hydroxide 、 盐酸羟胺 作用下， 以 1,4-二氧六环 、 aq. acetic acid 为溶剂， 生成 5-(4-methylphenyl)-1,2,4-oxadiazole
  参考文献：
  名称：

  6-O-acyl ketolide antibacterials

  摘要：

  其中R1、R2、R3、R4、W、X、X'、Y和Y'如本文所述，并且其中取代基具有描述中指示的含义。这些化合物可用作抗菌剂。

  公开号：

  US20030220272A1

文献信息

• [EN] 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS<br/>[FR] DERIVES DE 6-O-ACYL CETOLIDE D'ERYTHROMYCINE UTILES COMME AGENTS ANTI-BACTERIENS
  申请人：ORTHO MCNEIL PHARM INC

  公开号：WO2003050132A1

  公开（公告）日：2003-06-19

  6-O-Acyl ketolide antibacterials of formula (I): wherein R?1, R2, R3, R4¿, W, X, X', Y, and Y' are as described herein and in which the substituents have the meaning indicated in the description. These compounds are useful as antibacterial agents.

  公式（I）中的6-O-Acyl ketolide抗菌剂：其中R?1，R2，R3，R4¿，W，X，X'，Y和Y'如本文所述，并且其中取代基的含义如说明中所示。这些化合物可用作抗菌剂。
• 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1453847A1

  公开（公告）日：2004-09-08
• AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1697370B1

  公开（公告）日：2007-04-25
• PIPERIDINE/PIPERAZINE DERIVATIVES
  申请人：Janssen Pharmaceutica NV

  公开号：US20150322088A1

  公开（公告）日：2015-11-12

  The invention further relates to a DGAT inhibitor of formula including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —NR x —C(═O)—; —Z—C(═O)—; —Z—NR x —C(═O)—; —S(═O)p-; —C(═S)—; —NR x —C(═S)—; —Z—C(═S)—; —Z—NR x —C(═S)—; —O—C(═O)—; —C(═O)—C(═O)—; R 1 represents a 5-membered monocyclic heterocycle containing at least 2 heteroatoms; a 6-membered aromatic monocyclic heterocycle; or a 5-membered heterocycle containing at least 2 heteroatoms fused with phenyl, cyclohexyl or a 5- or 6-membered heterocycle; wherein each of said heterocycles may optionally be substituted; R 2 represents R 3 ; R 3 represents C 3-6 cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C 3-6 cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzo-dioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or 6-membered aromatic heterocycle may optionally be substituted; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.
• DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST
  申请人：Janssen Pharmaceutica NV

  公开号：US20180028660A1

  公开（公告）日：2018-02-01

  The present invention relates to combinations of a DGAT inhibitor and a peroxisome proliferator-activator receptor (PPAR) agonist or a prodrug thereof. The invention further relates to methods for preparing such combinations, pharmaceutical compositions comprising said combinations as well as the use as a medicament of said combinations. The present invention also relates to novel DGAT inhibitors. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicament of said compounds.